Your browser doesn't support javascript.
loading
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
Tagliamento, Marco; Morfouace, Marie; Loizides, Charalambos; Oliveira, Julio; Greillier, Laurent; Raimbourg, Judith; Toffart, Anne-Claire; Chatellier, Thierry; Cloarec, Nicolas; Sullivan, Ivana; Brasiuniene, Birute; Duruisseaux, Michael; Oselin, Kersti; Robert, Marie-Sophie; Fernandes, Carolina; Poncin, Arnaud; Blay, Jean-Yves; Besse, Benjamin; Girard, Nicolas.
Afiliación
  • Tagliamento M; Department of Cancer Medicine, Gustave Roussy, Villejuif, France. marco.tagliamento@unige.it.
  • Morfouace M; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy. marco.tagliamento@unige.it.
  • Loizides C; EORTC Headquarters, Bruxelles, Belgium.
  • Oliveira J; EORTC Headquarters, Bruxelles, Belgium.
  • Greillier L; Medical Oncology Department, Instituto Portugues de Oncologia do Porto Francisco Gentil, Porto, Portugal.
  • Raimbourg J; Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France.
  • Toffart AC; Department of Medical Oncology, Nantes Université, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
  • Chatellier T; Grenoble Alpes University, Grenoble Alpes Hospital, Grenoble, France.
  • Cloarec N; Clinique Mutualiste de l'Estuaire - Centre d'Oncologie, Saint Nazaire, France.
  • Sullivan I; Service d'Oncologie Médicale et Hématologie Clinique, Centre Hospitalier d'Avignon, Avignon, France.
  • Brasiuniene B; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Duruisseaux M; Department of Medical Oncology of National Cancer Institute, Faculty of Medicine of Vilnius University, Vilnius, Lithuania.
  • Oselin K; Department of Medical Oncology, CHU de Lyon - Hôpital Lyon Sud, Lyon, France.
  • Robert MS; Department of Chemotherapy, Clinic of Oncology and Hematology, North Estonia Medical Centre, Tallinn, Estonia.
  • Fernandes C; EORTC Headquarters, Bruxelles, Belgium.
  • Poncin A; EORTC Headquarters, Bruxelles, Belgium.
  • Blay JY; EORTC Headquarters, Bruxelles, Belgium.
  • Besse B; Department of Medicine, Centre Léon Bérard, Lyon, France.
  • Girard N; Paris-Saclay University, Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
NPJ Precis Oncol ; 8(1): 37, 2024 Feb 16.
Article en En | MEDLINE | ID: mdl-38366021
ABSTRACT
Arcagen (NCT02834884) is a European prospective study aiming at defining the molecular landscape of rare cancers for treatment guidance. We present data from the cohort of rare thoracic tumors. Patients with advanced pleural mesothelioma (PM) or thymic epithelial tumors (TET) underwent genomic profiling with large targeted assay [>300 genes, tumor mutational burden (TMB), microsatellite instability (MSI) status] on formalin-fixed paraffin-embedded (FFPE) or plasma samples. EORTC molecular tumor board (MTB) advised for biomarker-guided treatments. 102 patients recruited from 8 countries between July 2019 and May 2022 were evaluable 56 with PM, 46 with TET (23 thymomas, 23 thymic carcinomas). Molecular profiling was performed on 70 FFPE samples (42 PM, 28 TET), and 32 cases on ctDNA (14 PM, 18 TET), within a median turnaround time of 8 days from sample reception. We detected relevant molecular alterations in 66 out of 102 patients (65%; 79% PM, 48% TET), 51 of 70 FFPE samples (73%; 90% PM, 46% TET), and 15 of 32 plasma samples (47%; 43% PM, 50% TET). The most frequently altered genes were CDKN2A/B, BAP1, MTAP in PM and TP53, CDKN2A/B, SETD2 in TET. The TMB was low (mean 3.2 Muts/MB), 2 PM had MSI-high status. MTB advised molecular-guided treatment options in 32 situations, for 17 PM and 15 TET patients (75% clinical trial option, 22% off-label drug or compassionate use, 3% early access program). Molecular testing and MTB discussion were feasible for patients with rare thoracic cancers and allowed the broadening of treatment options for 30% of the cases.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido